These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 25548568)
41. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban. Guy S; Kitchen S; Maclean R; Van Veen JJ Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560 [TBL] [Abstract][Full Text] [Related]
42. Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity. Mina A; Favaloro EJ; Koutts J Blood Coagul Fibrinolysis; 2012 Apr; 23(3):203-7. PubMed ID: 22322136 [TBL] [Abstract][Full Text] [Related]
43. Effects of lidocaine, procaine, procainamide and quinidine on electrophysiological properties of cultured embryonic chick hearts. Riccioppo Neto FR; Sperelakis N Br J Pharmacol; 1985 Dec; 86(4):817-26. PubMed ID: 4075018 [TBL] [Abstract][Full Text] [Related]
44. Chromogenic substrates for activated partial thromboplastin time testing: are they worth using? Tripodi A Ric Clin Lab; 1989; 19(4):355-8. PubMed ID: 2517351 [TBL] [Abstract][Full Text] [Related]
45. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S. D'Angelo SV; Gilardoni F; D'Angelo A Thromb Haemost; 1989 Nov; 62(3):861-7. PubMed ID: 2531939 [TBL] [Abstract][Full Text] [Related]
46. Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions. Rao LV; Okorodudu AO; Petersen JR; Elghetany MT Clin Chim Acta; 2000 Oct; 300(1-2):13-21. PubMed ID: 10958859 [TBL] [Abstract][Full Text] [Related]
47. Shortened Activated Partial Thromboplastin Time Is Associated With Acute Ischemic Stroke, Stroke Severity, and Neurological Worsening. Lin CH; Kuo YW; Kuo CY; Huang YC; Hsu CY; Hsu HL; Lin YH; Wu CY; Huang YC; Lee M; Yang HT; Pan YT; Lee JD J Stroke Cerebrovasc Dis; 2015 Oct; 24(10):2270-6. PubMed ID: 26169548 [TBL] [Abstract][Full Text] [Related]
48. Correlation between activated clotting time and activated partial thromboplastin times. Smythe MA; Koerber JM; Nowak SN; Mattson JC; Begle RL; Westley SJ; Balasubramaniam M Ann Pharmacother; 2002 Jan; 36(1):7-11. PubMed ID: 11816262 [TBL] [Abstract][Full Text] [Related]
49. Behavior of diluted activated partial thromboplastin time in pregnant women with a lupus anticoagulant. Blanco AN; Grand BE; Pieroni G; Peñalva LB; Voto LS; Lazzari MA Am J Clin Pathol; 1993 Aug; 100(2):99-102. PubMed ID: 8356956 [TBL] [Abstract][Full Text] [Related]
50. Troubleshooting an isolate prolongation of activated partial thromboplastin time in a patient with acute myocardial infarction-a paradigmatic case report. Poli G; Castiglioni P; Montagnana M; Favaloro EJ; Lippi G Ann Transl Med; 2016 Nov; 4(21):426. PubMed ID: 27942517 [TBL] [Abstract][Full Text] [Related]
51. Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. Dubé C; Douketis JD; Moffat KA; Schulman S; Blais N Thromb Res; 2018 Nov; 171():62-67. PubMed ID: 30261356 [TBL] [Abstract][Full Text] [Related]
52. Coagulant and anticoagulant activities in Jatropha curcas latex. Osoniyi O; Onajobi F J Ethnopharmacol; 2003 Nov; 89(1):101-5. PubMed ID: 14522439 [TBL] [Abstract][Full Text] [Related]
53. Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. Rote NS; Dostal-Johnson D; Branch DW Am J Obstet Gynecol; 1990 Aug; 163(2):575-84. PubMed ID: 2117391 [TBL] [Abstract][Full Text] [Related]
54. Coagulation protein function: enhancement of the anticoagulant effect of acetaldehyde by sulfated glycosaminoglycans. Brecher AS; Adamu MT Dig Dis Sci; 2001 Sep; 46(9):2033-42. PubMed ID: 11575460 [TBL] [Abstract][Full Text] [Related]
55. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma. Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786 [TBL] [Abstract][Full Text] [Related]
56. Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor. Harenberg J; Reichel T; Malsch R; Hirsh J; Rustagi P Blood Coagul Fibrinolysis; 1996 Jun; 7(4):453-8. PubMed ID: 8839997 [TBL] [Abstract][Full Text] [Related]
58. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992 [TBL] [Abstract][Full Text] [Related]
59. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Reneke J; Etzell J; Leslie S; Ng VL; Gottfried EL Am J Clin Pathol; 1998 Jun; 109(6):754-7. PubMed ID: 9620035 [TBL] [Abstract][Full Text] [Related]